Syndax Pharmaceuticals, Inc. Stock Analysis & AI Score
Syndax Pharmaceuticals, Inc. (SNDX) has an ST Score of 53.9 (B-), driven by its Forecast (A) and held back by its Financial Strength (C). Analysts rate it Buy with a $37.00 price target (+105.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Syndax Pharmaceuticals, Inc. (SNDX) has an ST Score of 53.9 (B-), driven by its Forecast (A) and held back by its Financial Strength (C). Analysts rate it Buy with a $37.00 price target (+105.9% upside).
- Strongest
- ForecastA
- Weakest
- Financial StrengthC
All factor grades
- ForecastA
- GrowthB
- ValuationB-
- MomentumB-
- ProfitabilityC
- Financial StrengthC
- Piotroski3/9
Contact
SNDX stock: frequently asked questions
What is SNDX's ST Score?
Syndax Pharmaceuticals, Inc. (SNDX) has an ST Score of 53.9 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SNDX a buy, hold, or sell?
Analysts rate SNDX a Buy, with a price target of $37.00 (+105.9% vs the current price). Our ST Score grades it B- (53.9/100). The ST Score is a data-driven signal, not a recommendation.
What are SNDX's factor grades?
Valuation B-, Profitability C, Financial Strength C, Momentum B-, Growth B, Forecast A.
What is SNDX's valuation grade?
Syndax Pharmaceuticals, Inc. (SNDX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SNDX's growth grade?
Syndax Pharmaceuticals, Inc. (SNDX) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SNDX's profitability grade?
Syndax Pharmaceuticals, Inc. (SNDX) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SNDX's financial strength grade?
Syndax Pharmaceuticals, Inc. (SNDX) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SNDX?
The average analyst price target for Syndax Pharmaceuticals, Inc. (SNDX) is $37.00 from 22 analysts, which is +105.9% versus the recent price of $17.97.
What is SNDX's Piotroski score?
Syndax Pharmaceuticals, Inc. (SNDX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.